Burcu Yigit
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Burcu Yigit has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Cox Terhorst
Division of Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
3 shared publications Ninghai Wang
Division of Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
3 shared publicationsNicholas Chiorazzi
Karches Center for Oncology Research, The Feinstein Institute for Medical Research, Manhasset, New York
2 shared publications- Pablo Engel
Faculty of Medicine and Health Sciences, Biomedical Sciences University of Barcelona Spain
2 shared publications Roland W. Herzog
Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana
2 shared publicationsShih-Shih Chen
Karches Center for Oncology Research, The Feinstein Institute for Medical Research, Manhasset, New York
2 shared publications
Latest Publications
- 1 September 2019
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 7 (9) , 1485-1496
SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer
The tumor microenvironment in leukemia and solid tumors induces a shift of activated CD8+ cytotoxic T cells to an exhausted state, characterized by loss of proliferative capacity and impaired immunologic synapse formation. Efficient strategies and targets need to be identified to overcome T-cell exhaustion and further improve overall responses in the clinic. Here, we took advantage of the Eμ-TCL1 chronic lymphocytic leukemia (CLL) and B16 melanoma mouse models to assess the role of the homophilic cell-surface receptor SLAMF6 as an immune-checkpoint regulator. The transfer of SLAMF6+ Eμ-TCL1 cells into SLAMF6−/− recipients, in contrast to wild-type (WT) recipients, significantly induced expansion of a PD-1+ subpopulation among CD3+CD44+CD8+ T cells, which had impaired cytotoxic functions. Conversely, administering anti-SLAMF6 significantly reduced the leukemic burden in Eμ-TCL1 recipient WT mice concomitantly with a loss of PD-1+CD3+CD44+CD8+ T cells with significantly increased effector functions. Anti-SLAMF6 significantly reduced leukemic burden in the peritoneal cavity, a niche where antibody-dependent cellular cytotoxicity (ADCC) is impaired, possibly through activation of CD8+ T cells. Targeting of SLAMF6 affected tumor growth not only in B cell–related leukemia and lymphomas but also in nonhematopoietic tumors such as B16 melanoma, where SLAMF6 is not expressed. In vitro exhausted CD8+ T cells showed increased degranulation when anti-human SLAMF6 was added in culture. Taken together, anti-SLAMF6 both effectively corrected CD8+ T-cell dysfunction and had a direct effect on tumor progression. The outcomes of our studies suggest that targeting SLAMF6 is a potential therapeutic strategy.
- 1 September 2019
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 7 (9) , 1485-1496
SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer
The tumor microenvironment in leukemia and solid tumors induces a shift of activated CD8+ cytotoxic T cells to an exhausted state, characterized by loss of proliferative capacity and impaired immunologic synapse formation. Efficient strategies and targets need to be identified to overcome T-cell exhaustion and further improve overall responses in the clinic. Here, we took advantage of the Eμ-TCL1 chronic lymphocytic leukemia (CLL) and B16 melanoma mouse models to assess the role of the homophilic cell-surface receptor SLAMF6 as an immune-checkpoint regulator. The transfer of SLAMF6+ Eμ-TCL1 cells into SLAMF6−/− recipients, in contrast to wild-type (WT) recipients, significantly induced expansion of a PD-1+ subpopulation among CD3+CD44+CD8+ T cells, which had impaired cytotoxic functions. Conversely, administering anti-SLAMF6 significantly reduced the leukemic burden in Eμ-TCL1 recipient WT mice concomitantly with a loss of PD-1+CD3+CD44+CD8+ T cells with significantly increased effector functions. Anti-SLAMF6 significantly reduced leukemic burden in the peritoneal cavity, a niche where antibody-dependent cellular cytotoxicity (ADCC) is impaired, possibly through activation of CD8+ T cells. Targeting of SLAMF6 affected tumor growth not only in B cell–related leukemia and lymphomas but also in nonhematopoietic tumors such as B16 melanoma, where SLAMF6 is not expressed. In vitro exhausted CD8+ T cells showed increased degranulation when anti-human SLAMF6 was added in culture. Taken together, anti-SLAMF6 both effectively corrected CD8+ T-cell dysfunction and had a direct effect on tumor progression. The outcomes of our studies suggest that targeting SLAMF6 is a potential therapeutic strategy.
- 1 July 2019
- Published by Elsevier in Clinical Immunology
- Vol. 204, 3-13
SLAMF6 in health and disease: Implications for therapeutic targeting
- 1 July 2019
- Published by Elsevier in Clinical Immunology
- Vol. 204, 3-13
SLAMF6 in health and disease: Implications for therapeutic targeting
- Open Access
- 25 March 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (18) , 26346-26360
A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells
A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells
- 25 March 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (18) , 26346-26360
Open AccessA combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells
A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells